Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
NCT ID: NCT00952315
Last Updated: 2019-07-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
270 participants
INTERVENTIONAL
2009-08-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
NCT00351351
ShockPulse-SE vs. Trilogy Trial: Comparing the Performance of Two Intracorporeal Lithotripters for Removal of Large Renal Calculi
NCT03959683
Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney
NCT00959153
The StoneBreakerTM Trial
NCT00677196
Comparison of General Anaesthesia and Sedation on the Stone Fragmentation in Lithotripsy
NCT01361516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the last few years there have been new, improved versions of these devices introduced. These improved versions have addressed previous issues of probes clogging or breaking and cumbersome handpiece design. These include the Cyberwand (Cybersonics, Erie, PA), a dual probe ultrasonic device, Swiss Lithoclast Select (EMS, Switzerland) combining the pneumatic and ultrasonic modalities, and a novel device by LMA (Gland, Switzerland) called the StoneBreakerTM, a portable pneumatic device powered by CO2 cartridges.
We propose to compare each of these devices in a randomized study to see if one is better than another at removing kidney stones quickly and efficiently.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stonebreaker
Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
Stonebreaker
Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
Lithoclast Select
Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
Lithoclast Select
Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
Cyberwand
The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
Cyberwand
Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyberwand
Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
Stonebreaker
Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
Lithoclast Select
Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stone easily visible/measurable on plain abdominal imaging (KUB) or CT scan preoperatively
* Age 18 years or older
* Able to give informed consent
Exclusion Criteria
* Pregnancy
* Active urinary tract infection
* Extracorporeal shockwave lithotripsy within the last three months
* Complex stone anticipating multiple access sites
* Stones that are not clearly able to be measured on KUB or CT scan
* Inability to give informed consent
* Age less than 18 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana Kidney Stone Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Lingeman
James Lingeman, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James E Lingeman, MD
Role: PRINCIPAL_INVESTIGATOR
IU Health Physicians Urology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Scottsdale
Phoenix, Arizona, United States
Northwestern University
Chicago, Illinois, United States
IU Health Physicians Urology
Indianapolis, Indiana, United States
Johns Hopkins
Baltimore, Maryland, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Duke University
Durham, North Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
University of Wisconsin
Madison, Wisconsin, United States
University of British Columbia
Vancouver, British Columbia, Canada
The University of Western Ontario
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
International Kidney Stone Institute - Click here for more information about kidney stone disease
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.